2-2014

Metrics of the Gynecologic Oncology Literature Focused on Cited Utilization and Costs

Edward J. Pavlik
University of Kentucky, epaul1@uky.edu

John Hoff
University of Kentucky, john.hoff@uky.edu

Dylan Woolum
University of Kentucky, dylan.woolum@uky.edu

Yuqing Liang
University of Kentucky

Christiaan Wijers
University of Kentucky

See next page for additional authors

Follow this and additional works at: http://uknowledge.uky.edu/obgyn_facpub

Part of the Obstetrics and Gynecology Commons

Repository Citation
Pavlik, Edward J.; Hoff, John; Woolum, Dylan; Liang, Yuqing; Wijers, Christiaan; Schwartz, Melissa; Lefringhouse, Jason; and Baldwin, Lauren, "Metrics of the Gynecologic Oncology Literature Focused on Cited Utilization and Costs" (2014). Obstetrics and Gynecology Faculty Publications. Paper 2.
http://uknowledge.uky.edu/obgyn_facpub/2

This Article is brought to you for free and open access by the Obstetrics and Gynecology at UKnowledge. It has been accepted for inclusion in Obstetrics and Gynecology Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Authors
Edward J. Pavlik, John Hoff, Dylan Woolum, Yuqing Liang, Christiaan Wijers, Melissa Schwartz, Jason Lefringhouse, and Lauren Baldwin

This article is available at UKnowledge: http://uknowledge.uky.edu/obgyn_facpub/2
Metrics of the gynecologic oncology literature focused on cited utilization and costs.

Edward J Pavlik*, John Hoff, Dylan Woolum, Yuqing Liang, Christiaan Wijers. Melissa Schwartz, Jason Lefringhouse and Lauren Baldwin

Short title: *Utilization and cost of the gyn oncology literature*

Key words: impact factor, eigenfactor, article influence score, costs

ORIGINAL REPORT

Precise: Utilization of the gyn oncology literature sources is influenced by access to review or summary information, the size of the specialty, and financial considerations.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology
The University of Kentucky Chandler Medical Center
Lexington, Kentucky 40536-0293

Correspondence to:

*Edward J. Pavlik, Ph.D
Division of Gynecologic Oncology
Dept. of Obstetrics and Gynecology
University of Kentucky Medical Center
800 Rose Street
Lexington, KY 40536
Telephone 859/323-3830
Fax 859/323-1018
Email: epaul1@uky.edu

ABSTRACT
**Objective:** The newest findings on literature utilization relevant to gynecologic oncology were published by Thomson Reuters during June 2013 as determinants of journal standing. Our objective was to assess the different metrics reported for relative impact and cost for journals relevant to gynecologic oncology.

**Methods:** 55 journals were evaluated for Impact Factor (IF), 5 Year IF, Immediacy Index, Cited Half Life, Eigenfactor score (EF), Article Influence (AI) scores and subscription costs obtained from publisher information.

**Results:** *CA-A Cancer Journal for Clinicians* had the highest IF (101.78) & AI (24.502). The top EF cancer-specific journals were *the Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research* and *Oncogene*. Rankings for *Gynecologic Oncology* (409 articles, 18,243 citations) were IF= 3.929, 43/55, EF=0.038, 28/55, AI= 1.099, 44/55, all higher than the previous year. The IF improved from the 5 year IF in 31 journals, including *Gynecologic Oncology, 29/31*. Subscription costs for *Gynecologic Oncology* compared favorably to other journals.

**Conclusions:** The high utilization of review information in *CA-A Cancer Journal for Clinicians* and *Nature Review Cancer* illustrated by the IF coupled with a relatively low number of articles and short cited half life indicates that they serve as a leading source of quoted cancer statistics (*CA-A Cancer Journal for Clinicians*). Rankings for *Gynecologic Oncology* and the *International Journal of Gynecologic Cancer* have improved. Regardless of specialty size, the Impact Factor for *Gynecologic Oncology* is respectably strong. The decreased IF in 44% of the journals may reflect the international economy’s effect on cancer research.
Introduction

The great commission of gynecologic oncology is to advance the field. To this end, new information enters the literature and reaches individuals in practice and in training. We have examined the extent to which this information is cited using information formulated by Journal Citation Reports on the ISI Web of Knowledge [1]. In particular, this examination compares gynecologic oncology-specific citations to citations in a variety of journals that have published reports relevant to gynecologic oncology. The metrics considered here move considerations of quality and worthiness to readers beyond subjective views of reputation and command the attention of authors, sponsors and advertisers, while suggesting how metric improvement can be achieved.

Methods

The 55 journals selected for inclusion in this report all had published findings relevant to gynecologic oncology annually in the period in 2010-2012. Data on citations were obtained from Journal Citation Reports (JCR) on the ISI Web of Knowledge published by Thomson Reuters on subscription to the University of Kentucky libraries. The following definitions are used:

**Impact Factor 2012** = $A/B$ where

- $A =$ the number of times that articles published in that journal in 2010 and 2011 were cited by articles in indexed journals during 2012 and
- $B =$ the total number of "citable items" published by that journal in 2010 and 2011.

("Citable items" are usually articles, reviews, proceedings, or notes; not editorials or letters to the editor) [2].
**5 Year Impact Factor**: Average number of times articles from the journal published in the last five years have been cited in 2012. This measure can better gauge the impact of journals in fields where the influence of published research evolves over a longer period of time [3].

**Immediacy Index 2012** = \( \frac{A}{B} \) where

- \( A \) = the number of times articles published by the journal in 2012 were cited in indexed journals during 2012
- \( B \) = the number of articles, reviews, proceedings or notes published by the journal in 2012 [4].

**Cited Half Life**: the median age of the articles in the journal that were cited by other journals during 2012 [4].

**Eigenfactor score**: The Eigenfactor Score is measured using the 2012 citations in relation to citable items from the five previous years. While the Impact Factor weighs each citation to a journal equally, the Eigenfactor Score assigns a greater weight to those citations coming from influential journals, allowing these journals to exert greater influence in the determination of the rank of any journal which they reference. The Eigenfactor Score does not count journal self-citations. The sum of Eigenfactor Scores for all journals is 100; each journal's Eigenfactor Score is a percentage of this total [5,6,7].

**Article Influence Score**: The journal's Eigenfactor Score divided by the fraction of articles published by the journal. This determination is normalized so that the sum total of articles from all journals is 1 [8].
Thus, the mean Article Influence Score is 1.00 across the universe of journals. Consequently, a score greater than 1.00 indicates that articles in that particular journal have above-average influence, while a score less than 1.00 indicates that articles in that journal have a below-average influence.

**Cost Comparisons:** Subscription costs were obtained by visiting the web sites for each publication. Cost of some institutional subscriptions were obtained from the University of Kentucky library.

**Results**

**Metrics of Citation** 55 journals were evaluated. The *Proceedings of the National Academy of Science of the United States* published the most articles (3800) in 2012, followed by the *International Journal of Radiation Oncology Biology Physics* (908), the *International Journal of Cancer* (713), *Cancer* (650), and *Clinical Cancer Research* (642), Table 1. *Gynecologic Oncology* published more articles in 2012 than 41 of the journals (380 articles), while the *International Journal of Gynecologic Cancer* published more articles than only 29 of the journals (236 articles). The articles cited in 2012 for publications in 2010-11 define the Impact Factor and *CA-A Cancer Journal for Clinicians*, *the New England Journal of Medicine*, *the Lancet*, *Nature Review of Cancer* and the *Journal of the American Medical Association* ranked with the highest Impact factors. *Gynecologic Oncology* ranked 43rd with an Impact Factor of 3.929, while the *International Journal of Gynecologic Cancer* ranked 52nd with an Impact Factor of 1.941, Table 1. Immediacy defined in terms of same year publication and citation was highest for *CA-A Cancer Journal for Clinicians*, *the New England Journal of Medicine*, *the Lancet*, *the Journal of the American Medical Association* and *Lancet Oncology* with
Gynecologic Oncology ranking 42\textsuperscript{nd} and the International Journal of Gynecologic Cancer ranking 54\textsuperscript{th}. The staying power of articles as defined by the median age published in other journals in 2012 (Cited Half Life, in years) was highest for the American Journal of Obstetrics & Gynecology, Cancer, the Journal of the National Cancer Institute, Advances in Cancer Research and the Journal of the American Medical Association with Gynecologic Oncology ranked 18\textsuperscript{th} and the International Journal of Gynecologic Cancer ranked 33\textsuperscript{rd}, Table 1. Journal citations over a five year period weighted for influential journals (2008-2012: Eigenfactor score) were highest for the Proceedings of the National Academy of Science of the United States, the New England Journal of Medicine, the Journal of Clinical Oncology, Lancet, and Cancer Research, while Gynecologic Oncology ranked 28\textsuperscript{th} and the International Journal of Gynecologic Cancer ranked 40\textsuperscript{th}. The Article Influence Score can be taken as a measure of average influence of a journal’s articles five years after publication and by this measure CA-A Cancer Journal for Clinicians, the New England Journal of Medicine, Nature Review Cancer, Lancet, Cancer Cell and the Journal of the American Medical Association scored highest (>10), while Gynecologic Oncology demonstrated above average influence and the International Journal of Gynecologic Cancer showed influence well below average.

Our survey of the 2011-2012 period revealed that ~15\% of papers cited in Gynecologic Oncology had been published in Gynecologic Oncology. In addition, surveying the Gynecologic Oncology sections of the Journal of Clinical Oncology and of Cancer, showed that ~17\% and ~5\% of the references were to papers published in Gynecologic Oncology.
Examination of Cost  The most relevant subscription costs to gynecologic oncologists are likely to be *Gynecologic Oncology* & *the International Journal of Gynecologic Cancer* (Table 2 line A), *Cancer* and the *Journal of Oncology* (Table 2 line B) and *Obstetrics & Gynecology* and the *American Journal of Obstetrics and Gynecology* (Table 2 line C) totaling $2465 for members, $3003 for non-members and $8983 for libraries (Table 2 line 3). The total subscription cost to libraries and institutions for all 55 journals considered here is $109,512 and is ~5 times the cost to individual members (Table 2 line E). The mean cost to members of the 55 journals considered (Table 2 line F: $554±129 (SEM)) compares well with the subscription cost of *Gynecologic Oncology* ($563 journal alone, $625 annual membership with complementary journal subscription). However, subscription costs to the 6 journals most relevant to gynecologic oncology (Table 2 line D) are much less than the mean cost of subscription to 6 journals in the group of 55 journals under consideration (Table 2 line G).

Discussion

Ranking of the top 10 *Impact Factor* journals correlated well with the *5 year Impact Factor, Immediacy Index and Article Influence Score* in that the same journals ranked in the top 10 for each of these categories (Table 3). Only one of the top 10 *Impact Factor* journals was in the top 10 of the *Number of Articles* published in 2012, while 4 were in the top 10 of *Total Citations* in 2012 and 4 were in the top ten rank for *Cited Half-life*. Half of the top ten *Impact Factor* journals were among the journals with a top ten *Eigen Factor* score (Table 3). Thus, annual citation performance is least correlated with the number of articles published and connected about half the time with citations received,
their median half life and \textit{Eigen Factor} score. Consequently the metrics of citation are not driven by the volume of articles published. \textit{Gynecologic Oncology} was above the median ranking in terms of articles published, cited half-life and total citations for 2012 (Table 3), but it was below the median ranking in all other measures. The \textit{International Journal of Gynecologic Cancer} was above the median ranking in articles published, but below the median ranking in all other measures (Table 3).

Journals that publish reviews (\textit{CA-A Cancer Journal for Clinicians, Nature Review of Cancer, Nature Reviews Clinical Oncology}) are often cited with high immediacy and short half-life because they are subject to annual updating (and do not necessarily occur as citations in the most influential journals as indicated by the \textit{Eigen Factor} metric). Improvement in the current \textit{Impact Factor} relative to the previous five years was observed with 31 journals (56%), while the citation rate fell in 44% of the journals considered. Thus, a narrow 6% margin separates the journals that demonstrate improving citation from those that do not. Two tactics that could serve \textit{Gynecologic Oncology} to stay on track with improving annual \textit{Impact Factor} scores could be to include more reviews on gynecologic malignancies and to implement the inclusion of annual statistics on gynecologic malignancies. Such statistics should include and expand the gynecologic malignancies reported on beyond those covered in \textit{CA-A Cancer Journal for Clinicians} so that statistics uniquely available in \textit{Gynecologic Oncology} would push its \textit{Impact Factor} higher. Importantly, gynecologic cancer reviews and gynecologic cancer statistics should be made available on an Open Access basis to
maximize their utilization and contribution to the Impact Factor of *Gynecologic Oncology*.

Considered in the spectrum of medical specialty journals, *Gynecologic Oncology* is well-positioned. Of twenty seven selected medical specialties that were examined (Table 4), gynecologic oncology which ranked 22\textsuperscript{nd} in physician number (n=1007 [9,10]) had it’s lead journal’s Impact Factor ranked 13\textsuperscript{th}. The Impact Factor for *Gynecologic Oncology* (3.929) was better than the median Impact Factor for journals in small specialties (49-1854 physicians, median = 2.649) and better than the median Impact Factor for the lead journals of all specialties considered here (median = 3.569). Mid sized specialties (4493-19131 physicians) had lead journals with a greater median Impact Factor (5.644). Large specialties (27651-90269 physicians) had a median Impact Factor (3.877) slightly lower than *Gynecologic Oncology*. Considered in these terms, the current Impact Factor for *Gynecologic Oncology* is quite strong and respectable among journals for medical specialties. Impact Factors >10 considered here (Table 1) were either for multi-specialty journals or multi-discipline journals. We believe that *Gynecologic Oncology* currently serves both private practice and academic gynecologic oncologists extremely well because of it’s targeted content. We also believe that as a group, gynecologic oncologists are proud and very competitive. In this regard, we feel that an expectation exists for journal metrics that continuously improve. We believe that there is no downside to improving these metrics for those in private practice as well as in academic medicine and that the better the journal metrics, the better the Society of Gynecologic Oncologists will fair in the eyes of advertisers and sponsors.
In summary, *Gynecologic Oncology* performs well in terms of citation metrics and cost. It should be possible to further improve these metrics by introducing reviews and statistics on gynecologic malignancies.

The role of the medical journal must loom in the perspective of practitioners as a trustworthy source of information that carries both influence and advice. In this role it unifies the past with the present and must be counted on to have an ongoing outreach to future discovery and innovation. Authors want to publish in a quality place that draws attention to their work, a place that will be good enough to contribute to their career advancement. Readers want a source of significant information that is worthy of their time and subscription cost. The measure of quality and time worthiness has moved beyond subjective evaluation and now takes on the metrics of utilization, which while not totally perfect, provide comparative numeric standards that, like it or not, do command attention, especially of sponsors and advertisers. Not to be overlooked are new models embracing digital communication that have an influence on authors, readers, patients, sponsors and advertisers through information that reaches them through the Internet, Open Access, social media, blogs, Twitter, search engines, etc. In the end, the metrics of citation utilization will both influence and be influenced by an evolution of awareness brought forward by technology. As this occurs, journals must not lose sight of the significance of peer review [2]. This is the single most important process that can re-craft the submission by utilizing expert reviewers that raise questions, the answers to which can be incorporated in the final publication to enhance its quality [11]. In the end, with the literature practically “bursting at the seams” with the diverse opportunities made possible by the digital revolution [12], it will be quality that
determines readership and citations. The future holds but one thing and that is to continue to evolve so that specialty information is useful to those in the field of gynecologic oncology [13].

Conflict of Interest Statement

The authors declare that there are no conflicts of interest.
References


